Tradestie Institutional Equity Comparison Engine

GLUE vs AURA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AURA Overall Edge

AURA Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aura Biosciences, Inc. Common Stock (AURA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GLUE counters with relative strength in Valuation. Fundamentally, GLUE trades at 10.0x Forward P/E with -214.5% operating margin (+325.8% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, GLUE sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GLUE
GLUE 10.0x vs AURA N/M Fwd P/E
Growth & Margin Winner AURA
Op Margin -214.5% vs 0.0% ยท YoY +325.8% vs +0.0%
Momentum & Technical Winner AURA
1Y -36.4% vs +30.4% ยท 52W Pos 1% vs 52%
Options & Structure Winner AURA
BREAKDOWN (16th %ile IV) vs CONSOLIDATION (22nd %ile IV)
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.11
-2.77% 1D
Market Cap $795.5M
1M Return -6.47%
1Y Return -36.38%
Forward P/E 10.0x
Unified AI Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.21
+1.41% 1D
Market Cap $728.6M
1M Return +18.2%
1Y Return +30.38%
Forward P/E N/M
Unified AI Score
28.8 / 100 SELL
Tech 50.0 Fund 39.0 Flow 71.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GLUE -36.38% AURA +30.38% Spread: +66.76 pp (AURA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
GLUE TTM Op. Margin: -214.5% AURA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GLUE vs AURA. Trailing 12-month operating profitability (GLUE -214.5% vs AURA 0.0%) and valuation multiples (GLUE 10.0x vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GLUE (7) vs AURA (3)
Institutional Metric GLUE AURA Criterion Row Winner
Market Capitalization Scale $795.5M $728.6M Larger Scale GLUE
Trailing P/E Ratio Valuation 10.0x N/M Lower Multiple GLUE
Forward P/E Ratio Valuation 10.0x N/M Lower Multiple GLUE
Revenue Growth (YoY) Growth +325.8% +0.0% Higher Growth GLUE
Operating Margin (TTM) Profitability -214.5% 0.0% Higher Margin AURA
Net Profit Margin Profitability -186.2% 0.0% Higher Margin AURA
Return on Equity (ROE) Capital Efficiency -35.3% -61.7% Higher ROE GLUE
52-Week Range Position Momentum 1% ($9โ€“$26) 52% ($5โ€“$10) Stronger Trend AURA
Beta / 30D Volatility Risk Regime 0.94ฮฒ ยท 53% Vol 0.92ฮฒ ยท 75% Vol Lower Realized Risk GLUE
Unified Institutional Score Composite Signal 44.2 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite GLUE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GLUE vs AURA Buy Guide
GLUE BREAKDOWN
85d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live GLUE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AURA CONSOLIDATION
135d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live AURA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GLUE nor AURA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.